PDCD1 and acute myeloid leukemia: According to current data, checkpoint inhibitors apparently only have limited effect in AML patients.16 Concerning the mechanism of action in patients with IFI, we assume that nivolumab targets their lack of immune defense through PD-1 by restoring T-cell function and therefore strengthening host immunity.